NCCN Task Force Report: Bone Health in Cancer Care.
Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.
Gralow
Julie R
JR
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, USA.
Biermann
J Sybil
JS
Farooki
Azeez
A
Fornier
Monica N
MN
Gagel
Robert F
RF
Kumar
Rashmi N
RN
Shapiro
Charles L
CL
Shields
Andrew
A
Smith
Matthew R
MR
Srinivas
Sandy
S
Van Poznak
Catherine H
CH
D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary / Q000628:therapy; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D003952:Diagnostic Imaging / Q000379:methods; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment
D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates